Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
Bioregulator Peptides (Khavinson)
Overview
Bioregulator peptides are a class of short synthetic peptides, typically 2 to 4 amino acids in length, developed by Russian researcher Vladimir Khavinson based on sequences derived from organ-specific tissues. These peptides are theorized to exert tissue-specific regulatory effects by interacting with chromatin to modulate gene expression and restore age-related functional declines.
Mechanism of Action
Examples include thymus-derived peptides (Thymalin), pineal peptides (Epithalamin), and vascular peptides. The underlying hypothesis is that peptide bioregulators can reverse or slow aging by re-establishing youthful patterns of protein synthesis in target organs.
Research Summary & Key Findings
Studies published primarily in Russian and Eastern European journals report lifespan extension and reduced age-related pathology in animal models treated with Khavinson peptides. Clinical studies, including those on Epithalamin in elderly populations, have suggested benefits on biomarkers of aging and mortality, but these trials are generally small and lack replication in large-scale, Western, peer-reviewed settings. Regulatory approval is limited to Russia and former Soviet states, and international acceptance awaits independent validation and mechanistic clarification.
Clinical Status
Bioregulator Peptides (Khavinson) is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.
Administration Routes
References
Primary literature
- PubMed: "Bioregulator Peptides"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Bioregulator Peptides"
Registered interventional and observational studies, including status and phase.
- PubChem: "Bioregulator Peptides"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Longevity
Epithalon (Epitalon)
Research PhaseA synthetic tetrapeptide (Ala-Glu-Asp-Gly) based on the natural epithalamin peptide produced by the pineal gland. Epitha...
View detailsMOTS-c
Research PhaseA mitochondrial-derived peptide encoded by the 12S rRNA gene of mitochondrial DNA. MOTS-c is a 16-amino acid peptide tha...
View detailsHumanin
Research PhaseA 24-amino acid mitochondrial-derived peptide encoded within the 16S rRNA region of mitochondrial DNA. Humanin exerts cy...
View detailsNAD+ Precursors (NMN)
In Clinical TrialsNicotinamide mononucleotide (NMN) is a direct biosynthetic precursor to nicotinamide adenine dinucleotide (NAD+), a coen...
View detailsNo lawful pathway today
Bioregulator Peptides (Khavinson) is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so there is nothing for us to sell you here and no consultation to book. That can change: eight peptides moved back to a lawful pathway in February 2026.
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Join the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.